4.7 Article

Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 23, Pages 15584-15607

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01498

Keywords

-

Ask authors/readers for more resources

The presence of N-nitrosamines, which are derived from solvents, reagents, and sometimes the active pharmaceutical ingredient (API), at levels higher than acceptable in drug products, has prompted regulators to request a comprehensive review of their presence in all medicinal products. In the absence of rodent carcinogenicity data for novel N-nitrosamines derived from amine-containing APIs, a conservative class limit or the derivation of acceptable intakes (AIs) using structurally related surrogates with robust rodent carcinogenicity data is recommended. This guidance has significant implications for the pharmaceutical industry due to the large number of amine-containing drugs on the market. This perspective discusses the rate-limiting step in N-nitrosamine carcinogenicity and presents risk-mitigation strategies for managing potential N-nitrosamines in the preclinical discovery setting.
The detection of N-nitrosamines, derived from solvents and reagents and, on occasion, the active pharmaceutical ingredient (API) at higher than acceptable levels in drug products, has led regulators to request a detailed review for their presence in all medicinal products. In the absence of rodent carcinogenicity data for novel N-nitrosamines derived from amine-containing APIs, a conservative class limit of 18 ng/day (based on the most carcinogenic N-nitrosamines) or the derivation of acceptable intakes (AIs) using structurally related surrogates with robust rodent carcinogenicity data is recommended. The guidance has implications for the pharmaceutical industry given the vast number of marketed amine-containing drugs. In this perspective, the rate-limiting step in N-nitrosamine carcinogenicity, involving cytochrome P450-mediated alpha-carbon hydroxylation to yield DNA-reactive diazonium or carbonium ion intermediates, is discussed with reference to the selection of read-across analogs to derive AIs. Risk-mitigation strategies for managing putative N-nitrosamines in the preclinical discovery setting are also presented.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Chemistry, Medicinal

Chemical Research in Toxicology at 35: Recognizing the Impact of Professor Larry Marnett

Sarah Shuck, Amit S. Kalgutkar, Charles G. Knutson, Yinsheng Wang, Shana J. Sturla

CHEMICAL RESEARCH IN TOXICOLOGY (2022)

Article Medicine, Legal

Updating the Dermal Sensitisation Thresholds using an expanded dataset and an in silico expert system

Martyn L. Chilton, Anne Marie Api, Robert S. Foster, G. Frank Gerberick, Maura Lavelle, Donna S. Macmillan, Mihwa Na, Devin O'Brien, Catherine O'Leary-Steele, Mukesh Patel, David J. Ponting, David W. Roberts, Robert J. Safford, Rachael E. Tennant

Summary: This study updates the thresholds of dermal sensitisation by expanding the dataset and using in silico expert system. The new thresholds show similarity to the previously published ones, demonstrating their robustness and increasing confidence in their use.

REGULATORY TOXICOLOGY AND PHARMACOLOGY (2022)

Article Public, Environmental & Occupational Health

Nature-derived epoxy resins: Synthesis, allergenicity, and thermosetting properties of pinoresinol diglycidyl ether

Niamh M. O'Boyle, Ida B. Niklasson, David J. Ponting, Miguel A. Ortega, Tina Seifert, Andreas Natsch, Kristina Luthman, Ann-Therese Karlberg

Summary: This study describes a novel epoxy resin monomer derived from plant lignan, which has reduced allergenic effect while maintaining excellent properties. Experimental results show that this monomer does not exhibit skin sensitizing properties at certain concentrations and possesses promising cross-linking properties. It could be used for the development of safer epoxy resin materials.

TOXICOLOGY AND INDUSTRIAL HEALTH (2022)

Article Chemistry, Medicinal

What Makes a Potent Nitrosamine? Statistical Validation of Expert-Derived Structure-Activity Relationships

Robert Thomas, Rachael E. Tennant, Antonio Anax F. Oliveira, David J. Ponting

Summary: The discovery of carcinogenic nitrosamine impurities above safe limits in pharmaceuticals has created a need for methods to analyze the structure-activity relationship (SAR) using limited datasets. This study proposes a Bayesian multiple linear regression method that can estimate the effects of each structural feature independently, taking into account the combinations of features and reducing the impact of multiple testing.

CHEMICAL RESEARCH IN TOXICOLOGY (2022)

Article Chemistry, Medicinal

The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals

Joerg Schlingemann, Michael J. Burns, David J. Ponting, Carolina Martins Avila, Naiffer E. Romero, Mrunal A. Jaywant, Graham F. Smith, Ian W. Ashworth, Stephanie Simon, Christoph Saal, Andrzej Wilk

Summary: This article presents the findings of an analysis of over 12,000 small molecule drugs and drug impurities, revealing the prevalence of nitrosamines in pharmaceuticals. The study identifies potential nitrosamine precursors and highlights the risk to essential drug classes. It emphasizes the need for the application of established principles and open communication between the industry and regulatory authorities to ensure a balance between risk and benefit for patients.

JOURNAL OF PHARMACEUTICAL SCIENCES (2023)

Article Chemistry, Medicinal

Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat

Raman Sharma, Matthew S. Dowling, Kentaro Futatsugi, Amit S. Kalgutkar

Summary: We conducted SAR studies on amide-based inhibitors of DGAT2 and analyzed the metabolic liabilities of the liver-targeted DGAT2 inhibitor PF-06427878. Although PF-06427878 showed successful evasion of oxidative O-dearylation, its metabolic clearance was still high due to piperidine ring oxidation. Modification of the piperidine ring led to the discovery of azetidine 2 with lower clearance, but it underwent cytochrome P450-mediated oxidation and ring scission. Replacement of the azetidine substituent with a pyridine ring resulted in the more potent DGAT2 inhibitor 8, which mitigated the formation of electrophilic aldehyde metabolites. Further structural refinements in 8 led to the discovery of PF-06865571 (ervogastat), currently in phase 2 clinical trials for nonalcoholic steatohepatitis treatment.

CHEMICAL RESEARCH IN TOXICOLOGY (2023)

Review Chemistry, Medicinal

Utilizing mechanistic organic chemistry training to study drug metabolism in preclinical drug discovery/development

Deepak Dalvie, Amit S. S. Kalgutkar

Summary: A fundamental knowledge of applied organic chemistry is crucial for drug metabolism scientists involved in biotransformation studies or drug discovery. Understanding organic chemistry concepts helps elucidate complex metabolite structures and rationalize biotransformation mechanisms. Examples of using organic chemistry in studying toxicology relationships and metabolic activation pathways are highlighted in this manuscript.

MEDICINAL CHEMISTRY RESEARCH (2023)

Article Chemistry, Applied

Drawing a Line: Where Might the Cohort of Concern End?

David J. Ponting, Robert S. Foster

Summary: The definitions of the chemical classes in the Cohort of Concern (CoC) are based on structural alerts, particularly for N-nitroso compounds. Recent recalls have focused on potent carcinogenic dialkyl N-nitrosamine impurities. However, the class of "N-nitroso compounds" may be broader. This Perspective examines N-nitroso compounds at the edges of the cohort, questioning their classification based on changes in mechanism, metabolic activation potential, stability, or toxicity data.

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2023)

Article Chemistry, Medicinal

Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals

Michael J. Burns, David J. Ponting, Robert S. Foster, Benjamin P. Thornton, Naiffer E. Romero, Graham F. Smith, Ian W. Ashworth, Andrew Teasdale, Stephanie Simon, Joerg Schlingemann

Summary: The article discusses the mutagenic potential and risk of N-nitrosamines, as well as their formation mechanisms and distribution in small molecule drugs. The study finds that nitrosamines derived from secondary amine precursors have higher mutagenic potential, while those from tertiary amine precursors are more evenly distributed among different potency categories. The article also explores the impurity risk of secondary amine API and the quantification challenges of high potency nitrosamines.

JOURNAL OF PHARMACEUTICAL SCIENCES (2023)

Article Chemistry, Applied

The Nitrosamine Saga: Lessons Learned from Five Years of Scrutiny

Raphael Nudelman, Grace Kocks, Bruno Mouton, David J. Ponting, Joerg Schlingemann, Stephanie Simon, Graham F. Smith, Andrew Teasdale, Anne-Laure Werner

Summary: The N-nitrosamine (NA) saga in 2018 stemmed from small dialkyl N-nitrosamines in the synthesis of active pharmaceutical ingredients (APIs), but later investigations revealed a different type of NA impurities called nitrosamine drug-substance-related impurities (NDSRIs), which can form due to the presence of nitrosatable amine groups or nitrosating agents in APIs or API impurities. The unique properties of amine functional group in API synthesis make it irreplaceable. While efforts to control and analyze NA levels present significant challenges, the pharmaceutical industry is committed to implementing effective and realistic NA control strategies to ensure patient safety and secure access to important medicines.

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2023)

Article Medicine, Legal

A deep dive into historical Ames study data for N-nitrosamine compounds

Rachael E. Tennant, David J. Ponting, Andrew Thresher

Summary: Mutagenicity data is essential for the safety assessment of new drug compounds, and the Ames test is commonly used as a primary screen to evaluate mutagenic risk. However, it may not be sensitive enough to detect the mutagenic potential of N-nitrosamines, highly potent carcinogens. This study analyzes variations to the OECD 471-compliant Ames test and their impact on its predictive performance for carcinogenicity.

REGULATORY TOXICOLOGY AND PHARMACOLOGY (2023)

Article Medicine, Legal

Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies

S. P. Felter, D. J. Ponting, A. M. Mudd, R. Thomas, A. A. F. Oliveira

Summary: The unexpected discovery of N-nitrosamine (NA) impurities in pharmaceutical products has posed significant challenges for the industry and regulatory bodies. New NAs associated with active pharmaceutical ingredients have been found, many of which have limited or no safety data. Establishing Acceptable Intake (AI) limits for NA impurities has been done using a tiered approach, utilizing chemical-specific data, read-across, or a class-specific TTC limit. Despite the limitations of available data, it is important to use the best scientific information to assess NA impurities and ensure consumer safety while minimizing potential drug shortages.

REGULATORY TOXICOLOGY AND PHARMACOLOGY (2023)

Article Toxicology

Use of the TD50 99 % CI for single dose rodent carcinogenicity studies

Robert Thomas, Antonio Anax F. Oliveira, David J. Ponting, Andrew Thresher

Summary: TD50 is a widely used measure of carcinogenic potency, but its applicability is questioned due to low-quality studies from earlier years.

TOXICOLOGY LETTERS (2023)

Article Pharmacology & Pharmacy

Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir

Siennah R. R. Greenfield, Heather Eng, Qingyi Yang, Chunyang Guo, Laura Byrnes, Alyssa Dantonio, Graham West, Li Di, Amit S. S. Kalgutkar

Summary: Plasma protein binding studies showed significant species differences in the SARS-CoV-2 main protease inhibitor nirmatrelvir, particularly in dogs and rabbits. Further investigations revealed that these differences were primarily due to variations in albumin and alpha-1-acid glycoprotein binding affinity. These findings have important implications for the pharmacokinetics and efficacy of nirmatrelvir in different animal species.

XENOBIOTICA (2023)

Article Chemistry, Medicinal

Predicting Regioselectivity of AO, CYP, FMO, and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning

Mario Oeren, Peter J. Walton, James Suri, David J. Ponting, Peter A. Hunt, Matthew D. Segall

Summary: This study presents methods for predicting isoform-specific metabolism and the general CYP metabolism for preclinical species. The models use semi-empirical quantum mechanical simulations to estimate the reactivity of each site of metabolism and combine it with the orientation and steric effects of the enzyme isoforms' binding pockets. The resulting ligand-based models achieve high accuracy in predicting the metabolism sites.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

No Data Available